Thank you, and good afternoon on my behalf as well. Welcome to the Orion Q1 Results Webcast. Q1 of this year started very well with strong top-line growth of 11%. We generated €308.5 million in sales during the first quarter and €56 million in operating profit, with growth of 1%, resulting in an 18.2% profit margin. Cash flow was significantly better than in Q1 of 2023, where the transfer of pension funds was one contributor. And then a €30 million milestone payment we received from Bayer was made in the first quarter of 2023. And of course, good sales of Nubeqa® can also be seen here with royalties and product sales. And, regarding the operating profit, growth of 1% or even being flat compared to the revenues we have as planned and as communicated, invested more in R&D as well as our sales and marketing, and the results of that can, of course, be seen in the top-line growth. And here we take a closer look. Very good news regarding an almost $1 million growth. Also Easyhaler®, if you look here, the column shows almost as high growth, both in percentage and in absolute value with the Easyhaler® product portfolio. Also, the whole other portfolio. Excluding Animal Health, Fermion grew by 7.3%, and Animal Health also showed nice growth. We see a slight decline within the product portfolio, but clearly the decline is slowing down compared to the previous year. And hopefully, we'll clear these issues as we go along this year. The usual suspects are on the column. Some same drugs and dexmedetomidine managed to maintain continued, uh, generic competition. Uh, taking sales down here. On the operating profit. Volumes are clearly growing, but margins are declining due to the factors mentioned in previous slides. Explanations on Dex and Dexter's decline, very profitable products. And the new ones, replacing those, are not exactly as profitable. Royalties are evident; you can see the effect on the operating profit. And then fixed costs have grown by 12.3%. And that's in line with our previous estimate for the R&D costs, sales, and marketing costs. Here we can also say that some of our IAM costs have increased somewhat. We have a major program ongoing with the CIP renewal, and some of our programs and data need to be run on parallel systems during that. Now, our innovative medicines posted a 37.4% growth, a wonderful number. Let's remember that we start every year beginning with the royalty rate. So it's really a cumulative royalty rate from the beginning of every year. So, both the royalty rate and the sales will grow as the year proceeds. We've seen all-time high product deliveries to Bayer during the last quarter of last year, and actually the second highest ever during this first quarter. So the prognosis from that aspect is very good. And of course, as I said, other income is primarily from research purposes and we are significantly increasing our investments. And I will talk more about that when I get to the R&D pipeline. And we are continuing with Ztalmy® to, um. Uh, get the pricing and reimbursement in place in Europe. Another business area is in very good shape, even though there was a slight decline of 2.2%. If we deduct the impact of Dexdomitor® and Simdax® as well as Russia, from the previous year, we still had some sales in Russia in 2023, especially in the beginning of 2023. The generics portfolio grew by 5%. That's very healthy growth. It's currently assumed that generic sales in Europe will grow between 4 to 6%. So we are exactly in that space with our generics business. In Finland, which is the largest market for our generics, we were able to outperform the competitors, especially in the reference price market. We're also performing well in the OTC healthcare and consumer health markets. I think that I probably, unfortunately, skipped one slide here about branded products. Another division growing with double-digit numbers, showing almost 18% growth compared to Q1 2023, has clearly been a lead indicator. And the growth of this product, with more than 30% growth, is driven by the green wave in Europe, especially in the UK. But currently, we are also seeing the same kind of demand in Germany. And with Easyhaler® as our halo product, we can respond to this demand as the market entry coupon. I already discussed that it is almost at par with the previous year. And the Divina® series, which for us is mainly a hormonal gel with estradiol, is also growing compared to the previous year. All in all, a very good start for branded products as well as for the innovative and generics divisions, which shows that all of our businesses are contributing to the growth of the group or Orion group. And then the smaller businesses. Animal health is not being shy at all compared to the other divisions. There's healthy growth there as well, and Fermion keeps up with the external sales to other pharma companies and animal health sales grew also on the companion animals side with sedatives. We also launched Bonqat® in Europe and then also in the livestock business. Now, clinical pipeline. The change here from the previous one is that we have now completed ODM-111 phase one successfully, and we are expecting and preparing to report the results at some point next year at suitable scientific congresses. Otherwise, the portfolio remains as it has been so far. Sustainability continues to be a very strong item for Orion. Of course, we are preparing, as any other company, for the CSD reporting. And here you can see some of the major themes that are important for us. It's based on patient safety. We look at it from the supply perspective, of course, from the wider scope of pharmacovigilance and product quality as well. But in these days, it's not self-evident that the pharmaceuticals and medicines are available in pharmacies when you need them. And our service level is at an exceptional environmental level. We continue to work on that front. We are already ahead of our 2030 carbon neutral target for Scope 1 and 2 at Orion and are now expanding to Scope 3. We've also put a lot of emphasis on social responsibility, building a roadmap in the company, including our stakeholders and groups that we work with, and also, of course, the safety, putting focus on the safety of our employees. Now that you've seen the quarter one result, which we are very proud of, our quarter one was better than we had planned. And based on that, we are specifying our outlook for 2024 and specifying so that we raised the lower limit from 270 million to 280 million. So we have a more specified narrow scope for this year, from 280 million to €310 million of operating profit. The outlook for net sales remains the same as it was at the beginning of this year. And to this outlook and our understanding of how the year has started. It's important to understand that really, all our businesses know that Nubeqa is a wonderful growth driver, but as you saw, Easyhaler is as important with its fast growth and all our divisions are growing in a healthy way. If we deduct the effect of Simdax and Dexmedetomidine. Or decline the effects of Simdax and Dexmedetomidine. So all businesses are contributing to the growth of our net profit. Here, you can see on the slide the basis for the outlook, which I already discussed. So it's a new growth, and the cap on the product family is more as a flattish Easyhaler. Or animal health. Definitely growing. And the generics-based portfolio as well. Growing, which is a bit challenging. What is challenging is really to predict the timing of Nobel royalties, product sales, and some of the milestones. This year it's the €70 million sales milestone. So that's, we have a certain, how would I say, room for our outlook? Given these facts and R&D expenses are anticipated to increase significantly, and significantly means that it's on a different level than we are used to. It is understandable, as we are going to start a phase two program for our pain molecule with several phase two studies. And we still have several phase three trials ongoing with our partners. And also, we have molecules in our research pipeline which actually require much more of our budget since those are biologics. And then we need to do the CMC work, labor-intensive work, from an end date. So clearly more emphasis on R&D and also on sales and marketing, which has resulted in growth in all divisions. And this kind of puts together what I already said, that this makes it concrete and provides a framework for our strategy. We clearly have growing revenues. And all divisions play an important role there. And that allows us and enables us to spend more on R&D. We want to build the company's future beyond the 2030s and also invest in other areas like sales and marketing. Ensure that we have enough production capacity. And we have enough production capacity. Capacity? I'm sorry. We still have a bit of a technical challenge here. I was actually on this slide, thanks to... So, also, we want to invest in the production capacity as we are currently increasing capacity, increasing our digital capacity, and also our new backup capacity at Fermion. So all this growing revenue enables increasing the investments, growing EBIT and also growing our dividend. A clear package. And we really work within this framework. And now I'm going to jump one slide over to remind you of our financial objectives, which relate to the previous slide of our strategy. Now they move totally independently. Anyway, when I say that the revenues will grow, it's growth beyond 8%; no cover. Also, that we are able to grow faster with our operating profit, keeping the equity ratio at least at 50% and return of equity at least at 25%. So this gives a very strict, nice framework for all our investments and growth initiatives. And then the dividend payout of between 50 and 100%. Now I go back. Let's see how this works. It works well and we come to the capital allocation focus telling the same story. A very, very good story here. Internal pipeline as a first priority. Dividends: Maintaining, maintaining, and increasing the capacity where it's needed. Then in licensing or acquiring commercial or R&D assets, whatever is then suitable at which time and then acquisitions, if they really fulfill a criteria to produce growth in a way we want, for example, in such geographies where we are not yet operating, or if they provide some kind of a competence or capabilities that we need to fulfill our strategic targets. Now. All right. I think it's time to close on my behalf and invite Harry Carson here with me to answer your questions before we close the session. Please feel free to ask any questions.